Ocular Therapeutix (NASDAQ: OCUL) reported Q1 EPS of ($0.22), $0.04 better than the analyst estimate of ($0.26). Revenue for the quarter came in at $13.2 million versus the consensus estimate of $14.2 million.

GUIDANCE:

Ocular Therapeutix sees Q2 2022 revenue of $55-60 million, versus the consensus of $75.83 million.

For earnings history and earnings-related data on Ocular Therapeutix (OCUL) click here.